ArticleBritish journal of pharmacology2002
Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists.
Article in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- Exhaustive exercise abolishes REV-ERB-α circadian rhythm and shifts the kynurenine pathway to a neurotoxic profile in mice.The Journal of physiology · 2025Article
- Association between Coffee Consumption and Brain MRI Parameters in the Hamburg City Health Study.Nutrients · 2023Article
- Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease.Heliyon · 2021Article
- Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?International journal of tryptophan research : IJTR · 2020Review
- Quinolinic Acid and Nuclear Factor Erythroid 2-Related Factor 2 in Depression: Role in Neuroprogression.Frontiers in pharmacology · 2019Review
- Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation.Molecular neurobiology · 2018Article
- Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.Molecular neurobiology · 2018Article
- Caffeine prevents high-intensity exercise-induced increase in enzymatic antioxidant and NaRedox report : communications in free radical research · 2017Article
- Beta-trace Protein as a new non-invasive immunological Marker for Quinolinic Acid-induced impaired Blood-Brain Barrier Integrity.Scientific reports · 2017Article
- Article
- Cooperation of non-effective concentration of glutamatergic system modulators and antioxidant against oxidative stress induced by quinolinic acid.Neurochemical research · 2012Article
- Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.Neurotoxicity research · 2012Article
- The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.Parkinson's disease · 2011Article
- Adenosine A2A receptor deficient mice are partially resistant to limbic seizures.Naunyn-Schmiedeberg's archives of pharmacology · 2009Article
- Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.Neurotoxicity research · 2009Article
- Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Current pharmaceutical design · 2008Review
- Tryptophan, adenosine, neurodegeneration and neuroprotection.Metabolic brain disease · 2007Review
- Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.Experimental brain research · 2005Article
- Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.Purinergic signalling · 2005Article
- Involvement of quinolinic acid in AIDS dementia complex.Neurotoxicity research · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
1. Quinolinic acid may be an important endogenous excitotoxin, but its concentrations in brain are low. We have therefore attempted to determine whether its neurotoxicity can be increased by the simultaneous presence of free radicals. 2. Quinolinic acid was injected into the hippocampus of anaesthetized rats at doses of 40 and 80 nmols which produced little neuronal loss, and 120 nmols which produced over 90% neuronal loss. 3. A mixture of xanthine and xanthine oxidase, a known source of free radical reactive oxygen species, also generated little damage alone, but killed over 80% of CA1 neurons when combined with 80 nmols of quinolinic acid. Similarly, the nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) potentiated the damage produced by quinolinic acid. 4. The glutamate antagonist 5,7-dichlorokynurenic acid prevented the damage produced by 120 nmols of quinolinic acid, but not that produced by quinolinic acid plus xanthine/xanthine oxidase, indicating that damage was not simply the result of free radical enhancement of NMDA receptor activation. 5. Three chemically dissimilar antagonists at adenosine A(2A) receptors prevented the damage caused by quinolinic acid and xanthine/xanthine oxidase or by quinolinic acid plus SNAP. 6. It is concluded that reactive oxygen species can potentiate the neurotoxicity of quinolinic acid. The site of interaction is probably distal to the NMDA receptor. Blockade of adenosine A(2A) receptors can protect against this combined damage, suggesting potential value in the prevention of brain damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.